Likewise, the randomized, multicenter phase II EMERGING-CTONG 1103 trial evaluated erlotinib against neoadjuvant chemotherapy (gemcitabine plus cisplatin) in patients with stage IIIA N2 EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.